最新消息
News
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101漢康生技創新 SIRPα/CD47 融合蛋白生物藥 HCB101 獲日本專利核准
HanchorBio Secures Japanese Patent for Engineered SIRPα […]
1 月 23, 2026
Read more
HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026漢康生技參與 2026 年 摩根大通健康醫療大會
HanchorBio Participating in the J.P. Morgan Healthcare […]
1 月 14, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation漢康生技於2026 ASCO GI消化道腫瘤大會發表 HCB101 聯合標準治療在二線胃癌之臨床數據
HanchorBio Reports High Objective Response Rate with HC […]
1 月 09, 2026
Read more
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio 2025 Milestones 漢康生技 2025 年度里程碑總回顧
漢康生技 2025 年度里程碑總回顧 漢康為癌症及自體免疫疾病病患，打造具臨床突破力的創新抗癌生物藥。 漢康生 […]
12 月 29, 2025
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more
【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]
12 月 03, 2025
Read more